Processa Pharmaceuticals, Inc. — Director's Dealing 2021

Dec 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-12-03

Reporting Person: Yorke Justin W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-03	Common Stock	S	5500	$4.8362	Disposed	538617	Indirect
2021-12-06	Common Stock	S	4200	$4.7104	Disposed	534417	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9323	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8001 to $5.01, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.5601 to $4.80, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.